EBiSC – the first European bank for induced pluripotent stem cells
Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) join forces with small and medium-sized enterprises and academia in an Innovative Medicines Initiative supported public private partnership project to establish the leading facility for the storage and distribution of induced pluripotent stem cells in Europe.
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase 1b clinical trial of PROHEMA® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell transplantation for hematologic malignancy (the ProHema-01 trial).
Cerebral Palsy and the Potential of Cord Blood Stem Cells
Cord Blood Registry® (CBR®) is fueling innovation in newborn stem cell research. CBR is partnering with two preeminent institutions, the University of Texas Health Science Center at Houston and Georgia Regents University, to establish FDA-regulated clinical trials investigating whether an intravenous infusion of a child's own cord blood cells, banked at the time of their birth, will lessen the symptoms of cerebral palsy.
U.S. National Institutes of Health to Commence New Study of Pluristem’s PLX Cells for Acute Radiation Syndrome Treatment
Pluristem Therapeutics, Inc. a leading developer of placenta-based cell therapies, announced that the U.S. National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, will commence a mechanism-of-action study of Pluristem’s PLacental eXpanded RAD cells for the treatment of acute radiation syndrome.
REGiMMUNE Begins Enrollment for Phase II Clinical Trial for Graft versus Host Disease
REGiMMUNE Corporation announced that it has begun a Phase II study of its proprietary compound RGI-2001 for GvHD associated with hematopoietic stem cell transplantation. The study was initiated following the successful completion of a Phase I study in patients with bone marrow or peripheral blood stem cell transplantation leukemia patients following chemotherapy.
TotipotentRX and ThermoGenesis Achieve Bone Marrow Stem Cell Transplant Milestone
ThermoGenesis Corp. a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease announced the TotiPotentRX cellular therapy clinical team in partnership with Fortis Healthcare, Gurgaon (New Delhi) has achieved its 20th pediatric bone marrow transplant.
Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study
Gamida Cell announced that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma.
SRI International Launches FASTcell Screening Services for Identification and Characterization of Rare Circulating Cancer Cells
SRI International announced the availability of its FASTcell™ technology offered as a testing service for detecting and characterizing rare circulating tumor cells from whole blood samples.
MEI Pharma Receives Orphan Status for Lead Drug Candidate Pracinostat for Treatment of Acute Myeloid Leukemia
MEI Pharma, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s investigational drug Pracinostat for the treatment of acute myeloid leukemia,
Igenica Enrolls First Patient in Phase I Trial of IGN523 to Treat Acute Myeloid Leukemia
Igenica Biotherapeutics announced that the first patient has been dosed in a Phase I clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML). The trial is designed to assess the safety, pharmacokinetics and clinical activity of IGN523, an antibody targeting CD98, a cell surface protein frequently overexpressed on AML cells.